Literature DB >> 27841011

Portal cavernoma cholangiopathy: diagnosis, imaging, and intervention.

Lauren N Moomjian1, Sarah G Winks2.   

Abstract

The term portal cavernoma cholangiopathy refers to the biliary tract abnormalities that accompany extrahepatic portal vein obstruction (EHPVO) and subsequent cavernous transformation of the portal vein. EHPVO is a primary vascular disorder of the portal vein in children and adults manifested by longstanding thrombosis of the main portal vein. Nearly all patients with EHPVO have manifestations of portal cavernoma cholangiopathy, such as extrinsic indentation on the bile duct and mild bile duct narrowing, but the majority are asymptomatic. However, progressive portal cavernoma cholangiopathy may lead to severe complications, including secondary biliary cirrhosis. A spectrum of changes is seen radiologically in the setting of portal cavernoma cholangiopathy, including extrinsic indentation of the bile ducts, bile duct stricturing, bile duct wall thickening, angulation and displacement of the extrahepatic bile duct, cholelithiasis, choledocholithiasis, and hepatolithiasis. Radiologists must be aware of this disorder in order to provide appropriate imaging evaluation and interpretation, to facilitate appropriate treatment and to distinguish this entity from its potential radiologic mimics.

Entities:  

Keywords:  Cavernous transformation of the portal vein; Extrahepatic portal vein obstruction; Portal cavernoma cholangiopathy; Portal vein thrombosis

Mesh:

Year:  2017        PMID: 27841011     DOI: 10.1007/s00261-016-0957-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  2 in total

1.  Portal Cavernoma Mimicking Pancreatic Malignancy.

Authors:  Vivian M Ussui; Lavinia Goldstein; Enrico Souto; Cynthia Levy
Journal:  ACG Case Rep J       Date:  2018-02-28

2.  Meso-Rex bypass shunt vs. transposition shunt for cavernous transformation of portal vein in children.

Authors:  Yong Lv; Lihui Pu; Jiulin Song; Jian Yang; Guoyou Zou; Jiayin Yang; Bo Xiang; Shuguang Jin
Journal:  Front Pediatr       Date:  2022-09-07       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.